BioVector® DERL-2 人肝脾加马德尔塔 T 细胞淋巴瘤细胞系 / BioVector® DERL-2 Human Hepatosplenic Gamma-Delta T-Cell Lymphoma Cell Line

通用定义BioVector® DERL-2 是一种源自人类的永生化肝脾 γδ T 细胞淋巴瘤（Hepatosplenic Gamma-Delta T-Cell Lymphoma）悬浮增殖型细胞系。该细胞系于 1995 年在疾病进展期从一名 30 岁患有恶性 T 细胞非霍奇金淋巴瘤（T-Cell NHL）的男性患者外周血中分离并成功建立，保藏于德国微生物菌种和细胞培养物保藏中心（DSMZ），编号为 ACC 531。其同步分离的姐妹株细胞系为 BioVector® DERL-7。

在肿瘤免疫学，临床转化医学以及罕见血液恶性肿瘤病理研究中，BioVector® DERL-2 是一株极其罕见的、具有严格白细胞介素 2（IL-2）细胞因子依赖性的临床进展期 T 细胞淋巴瘤细胞模型。它高度保留了人原发性肝脾 T 细胞淋巴瘤的特征性染色体变异（如 7q 臂内倒位或等臂染色体变异）以及特定的融合基因表达。它被广泛用作评估新型抗 T 细胞淋巴瘤靶向小分子，免疫调节剂，以及解析人源 T 细胞恶性转化和细胞因子逃逸级联响应的核心体外研究工具。

BioVector® DERL-2 技术参数

1. 细胞形态与核心分子遗传学特征

• 形态特征 属于典型的悬浮生长细胞。镜下表现为大小不一，呈现高度多形性（Multiformed）的细胞群体，它们极易自发聚集形成大型悬浮细胞簇，培养物基质中会持久自发伴随一定数量的细胞碎片。

• 特异性细胞因子依赖（生命线） 该细胞在体外维持中对 白细胞介素 2（IL-2） 存在绝对的生存依赖。如果缺乏 IL-2，细胞会迅速激活内源性凋亡途径导致全盘死亡。

• 免疫表型分布（表面标记物） 根据 DSMZ 权威免疫抗原谱鉴定结果：

  • 阳性表达 CD2, CD6, CD7, CD8 状态为强阳性。

  • 阴性表达 CD3, CD4, CD5, CD13, CD19, CD34 均为阴性。

  • 特殊注意 其抗原受体复合体 TCR alpha/beta 以及 TCR gamma/delta 在长期传代株的表面丰度分析中表现为阴性。

• 染色体与分子遗传特征 具有典型的人类超二倍体核型。其包含有 i(7q) 等臂染色体变异，该变异是临床上肝脾 T 细胞非霍奇金淋巴瘤高度特异性的细胞遗传学标志。此外，经反转录多聚酶链式反应（RT-PCR）证实，该细胞系稳定转录表达 CD53::PDGFRB 融合基因，这为其下游酪氨酸激酶通路持久活化提供了分子基础。

2. 培养条件

• 推荐基础培养基 优质的 BioVector® RPMI-1640 培养基（占比 80%）。

• 推荐血清体系 20% 高比例且经过热灭活处理的 BioVector® Fetal Bovine Serum 胎牛血清（高浓度血清对维持其活力至关重要）。

• 绝对核心添加物（关键） 必须在完全培养基中额外添加 20 ng/mL 的重组人白细胞介素 2（human IL-2）。

• 培养环境 37 摄氏度，5% 二氧化碳。

• 倍增时间与传代密度 细胞生长相对缓慢，细胞倍增时间约为 60 小时。

  • 接种限度 传代接种时必须维持极高的起始细胞密度，建议初始接种丰度不低于 $1.0\times 10^6\text{cells/mL}$。为了给其创造微环境浓度，推荐首选在 6 孔板或 12 孔板等小体积容器中进行密集培养，切勿直接接种至大体积培养瓶。

  • 饱和分瓶 当悬浮细胞簇大量增殖且饱和密度达到约 $2.5\times 10^6\text{cells/mL}$ 时，按照 1:2 的紧密比例进行常规分瓶，大约每 2-3 天补充一次新鲜的含 IL-2 的培养基。

主要科研应用

1. 细胞因子信号网络与选择性分化逃逸机制

• 独立突变株筛查 BioVector® DERL-2 是研究细胞因子从“依赖”走向“不依赖”恶性演进的天然沙盘。通过人为故意给予细胞因子匮乏压力，可用来诱导和解析突变株是如何通过激活 STAT5B（例如携带 STAT5BN642H 获得性功能突变）来实现因子独立性生长的。

2. 罕见 T 细胞淋巴瘤靶向小分子筛选

• PDGFRB 抑制剂药效 鉴于其表达 CD53::PDGFRB 激酶融合蛋白，该细胞系可作为绝佳的靶点验证工具，用于评估各种新型酪氨酸激酶抑制剂（TKI）对异常活化淋巴瘤细胞生存率的抑制效果。

实验操作注意事项（避坑指南）

• 严防因子匮乏引发的克隆衰退（核心雷区）

  高风险预警 长期处于亚致死剂量 IL-2（如低于 10 ng/mL）或接种密度过低的环境中，会强行促使培养物中极少数发生杂带突变的选择性“非依赖型亚克隆”过度生长。这种过度生长会彻底改变细胞系原有的生物学表型，导致实验数据失真。每次配置新培养基时，必须使用高精度移液器现配现加人 IL-2。

• 冻存与复苏技巧

  • 该细胞对常规含 10% DMSO 基础血清冻存液敏感度较差，复苏存活率低。强烈建议使用 BioVector® 推荐的无血清专用细胞冻存液（或高比例血清 70% 培养基加 20% 血清加 10% DMSO）进行程序降温冻存。复苏贴壁前 24 小时内，请勿频繁摇晃或换液，静置等待其自然形成初级悬浮簇。

技术指标简表

BioVector® DERL-2 Human Hepatosplenic Gamma-Delta T-Cell Lymphoma Cell Line

General DefinitionBioVector® DERL-2 is an immortalized human suspension cell line derived from hepatosplenic gamma-delta T-cell lymphoma. It was originally isolated in 1995 from the peripheral blood of a 30-year-old male patient suffering from aggressive T-cell non-Hodgkin lymphoma during disease progression. Curated by the German Collection of Microorganisms and Cell Cultures, its official repository accession is DSMZ ACC 531. A simultaneous sister cell line obtained from the same individual is cataloged as BioVector® DERL-7.

In tumor immunology and clinical translational medicine, BioVector® DERL-2 represents a rare, dedicated research model characterized by its strict Interleukin-2 (IL-2) dependence. The cells highly retain typical cytogenetic alterations of primary hepatosplenic lymphoma, such as the characteristic isochromosome 7q. It is widely employed as an in vitro framework to test novel anti-T-cell lymphoma therapeutics, evaluate immunomodulators, and study the molecular dynamics governing cytokine addiction and pathway hijacking in malignant T-cells.

BioVector® DERL-2 Technical Specifications

1. Morphology and Core Molecular Genetics

• Morphological Appearance Classified as a suspension cell line. Under phase-contrast microscopy, cells present as multiformed leukocytes varying in size, which spontaneously aggregate into large floating clusters. A notable background of cellular debris is typically present throughout all growth stages.

• Strict Cytokine Dependency Demonstrates absolute dependence on Interleukin-2 (IL-2) for survival and propagation. Deprivation of IL-2 swiftly triggers intracellular apoptotic pathways, culminating in total culture collapse.

• Immunophenotypic Profiling (Surface Markers) Characterized by the following antigen configuration based on authenticated repository mapping:

  • Positive Expressions Strongly positive for CD2, CD6, CD7, and CD8.

  • Negative Expressions Confirmed negative for CD3, CD4, CD5, CD13, CD19, and CD34.

  • Special Note The antigen receptors TCR alpha/beta and TCR gamma/delta register as negative on the surface of long-term cultivated stocks.

• Cytogenetic Landscape Exhibits a human hyperdiploid karyotype naturally featuring the i(7q) isochromosome rearrangement, a hallmark cellular marker pathognomonic for clinical hepatosplenic T-cell NHL. Additionally, RT-PCR validation confirms robust transcript expression of the CD53::PDGFRB fusion gene, driving downstream tyrosine kinase signal activation.

2. Culture Conditions

• Recommended Basal Media Formulated with 80 percent BioVector® RPMI-1640 basal medium.

• Serum Supplementation Augmented with 20 percent heat-inactivated BioVector® Fetal Bovine Serum. Higher serum concentrations are necessary to protect cell integrity.

• Essential Cytokine Admixture (Critical) The complete medium must be continuously supplemented with 20 ng/mL of recombinant human Interleukin-2 (human IL-2).

• Incubation Parameters 37 degrees Celsius in a humidified atmosphere charged with 5 percent Carbon Dioxide.

• Doubling Kinetics and Seeding Density Displays slow growth kinetics, with an average doubling time of 60 hours.

• Seeding Concentration To maintain vital autocrine conditioning, cells must be seeded at a high initial density of no less than $1.0\times 10^6\text{cells/mL}$. Cultivation should be initiated in smaller volumes, such as 6-well or 12-well culture plates, rather than large flasks.

• Subculturing Cascade Upon reaching a maximum saturated density of approximately $2.5\times 10^6\text{cells/mL}$, split the suspension aggregates at a conservative 1:2 ratio every 2 to 3 days, feeding with freshly prepared IL-2 enriched medium.

Primary Research Applications

1. Cytokine Signaling Networks and Factor-Independent Escape Mapping

• Subclone Outgrowth Assays BioVector® DERL-2 serves as an ideal platform to model how cytokine-dependent cells transition into autonomous growth. Applying selective pressure through deliberate cytokine insufficiency allows investigators to capture and study the outgrowth of factor-independent subclones driven by compensatory downstream mutations like STAT5B alterations.

2. Target Validation for Rare T-Cell Lymphomas

• PDGFRB Kinase Inhibition Because it expresses the CD53::PDGFRB fusion protein, this cell line is utilized to evaluate the efficacy of next-generation tyrosine kinase inhibitors designed to block aberrant proliferation pathways in malignant lymphomas.

Experimental Handling and Quality Guidelines

• Prevention of Subclone Selection (Critical Warning)

  High-Risk Operational Alert Maintaining the cells under suboptimal culture settings, such as inadequate cell densities or insufficient IL-2 levels, inadvertently accelerates the selective outgrowth of factor-independent mutants. This phenotypic drift fundamentally alters the baseline properties of the model. Fresh human IL-2 must be added precisely to each feed preparation.

• Cryopreservation and Thawing Logistics

  • These cells show high sensitivity to traditional freezing media containing standard serum and 10 percent DMSO, which often leads to poor post-thaw recovery. It is highly recommended to use a specialized serum-free freezing medium. Following initial thawing, leave the suspension unmanipulated for the first 24 hours to let primary cell aggregates re-establish.

Technical Data Summary

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net